Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Iksuda Therapeutics
Iksuda Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Donaldson's Isolere Bio launches IsoTag reagent for optimal AAV purification
The IsoTag AAV reagent can purify adeno associated viruses for research purposes, achieving up to an 85% in yield
Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA
The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
groninger showcases filling and closing solutions for OTC pharma at Pack Expo
Discover the flexcare 101 and flexfill machines designed for enhanced efficiency and flexibility in pharmaceutical production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Finance
ADC developer Iksuda Therapeutics closes $47m financing round
The company’s lead preclinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers
Research & Development
Iksuda releases first data on ADC efficacy on tumour regression
British next-gen Antibody Drug Conjugates developer says its IKS01 allows for the targeted delivery of a potent cytotoxic payload to tumours
Pharmaceutical
Iksuda and Femtogenix ink solid tumour agreement
Iksuda has stated it will use Femtogenix payload molecules to progress its lead antibody drug conjugate
Media
Glythera announces corporate name change and rebranding
Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Ingredients
Glythera appoints Professor Kerry Chester to SAB
Recruitment
Glythera appoints Chief Scientific Officer and strengthens SAB
Subscribe now